Emerging Indications for Hyperbaric Oxygen Treatment

Sponsor
Jay C. Buckey Jr.
Study ID
NCT07240649
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute COVID-19
  • Anastomosis, Leaking
  • Avascular Necrosis of Bone
  • Axonotmesis
  • Branch Retinal Artery Occlusion
  • Calciphylaxis
  • Cartilage Injury
  • Central Retinal Vein Occlusion
  • Chronic Anal Fissure
  • Clostridium Enterocolitis
  • Crohn Disease
  • Cystitis Chronic
  • Decubitus Ulcer
  • Epidermolysis Bullosa (EB)
  • Facial Filler Injections
  • Femoral Head Necrosis
  • Frostbite
  • Graft-vs-Host Disease
  • Greater Trochanteric Pain Syndrome
  • Head Trauma
  • Hypospadias
  • Inclusion Body Myositis
  • Invasive Fungal Infection
  • Ischemic Bowel
  • Ligament Injury
  • Malignant Otitis Externa
  • Multiple Sclerosis
  • Nonarteritic Anterior Ischemic Optic Neuropathy
  • Osteonecrosis
  • Pneumatosis Intestinalis
  • Post-COVID-19 Condition
  • Pouchitis
  • Prosthesis Related Infections
  • Pterygium
  • Pyoderma Gangrenosum
  • Raynaud Syndrome
  • Rectovaginal Fistula
  • Tinnitus
  • Ulcer Ischemic
  • Ulcerative Colitis
  • Vasculitic Ulcer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hyperbaric oxygen treatment (HBOT) — DEVICE
    Hyperbaric oxygen refers to oxygen given at pressures higher than atmospheric pressure (higher than 1.4 ATA) in pressurized chamber.
  • 100% Oxygen — DRUG
    Receiving 100% oxygen as part of HBOT

Study Details

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.

Key Dates

First listed
Nov 21, 2025
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2035
Completion
Dec 31, 2035

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hyperbaric oxygen treated group
    This individuals will be receiving hyperbaric oxygen treatment for the condition listed in the conditions section. Patients come daily for the treatment and receive hyperbaric oxygen at 2.0-2.4 atmospheres absolute for 90 minutes at the treatment pressure.

Primary Outcome Measure

Quality of Life EuroQOL EQ-5D-5L Questionnaire [ Time Frame: Within one week of starting HBO2 and within one week of ending HBO2 treatment ]

Central Contacts

Find similar trials

Nationwide
Crohn's disease trialsMultiple sclerosis trialsUlcerative colitis trialsGastroenterology trialsInflammatory bowel disease trialsAutoimmune disease trialsNeurology trialsBrain disorders trials

Related Studies